Mouse Anti-VWF Recombinant Antibody (clone SZ123) (CAT#: HPAB-M0250-YC)

Figure 1 Anti-human VWF antibody SZ-123 cross-reacts with Rhesus monkey VWF.

SZ-123 blocked binding of plasma VWF from Rhesus monkey to human collagen type III coated plates and this binding is dose dependent.

Zhao, Y. M., Jiang, M., Ji, S. D., He, Y., Shen, F., Li, X. M., & Ruan, C. G. (2013). Anti-human VWF monoclonal antibody SZ-123 prevents arterial thrombus formation by inhibiting VWF-collagen and VWF-platelet interactions in Rhesus monkeys. Biochemical Pharmacology, 85(7), 945-953.

Figure 2 SZ-123 inhibits platelet thrombosis in vivo.

(A) Representative charts of CFRs showing the effect of SZ-123 on platelet thrombosis in femoral arteries of Rhesus monkeys. (B) Inhibition of CFRs measured within 1 h after administration of different doses of SZ-123.

Zhao, Y. M., Jiang, M., Ji, S. D., He, Y., Shen, F., Li, X. M., & Ruan, C. G. (2013). Anti-human VWF monoclonal antibody SZ-123 prevents arterial thrombus formation by inhibiting VWF-collagen and VWF-platelet interactions in Rhesus monkeys. Biochemical Pharmacology, 85(7), 945-953.

Figure 3 Ex vivo analysis of plasma SZ-123 levels, VWF occupancy, and inhibition by SZ-123 on VWF binding to collagen.

(A) Plasma SZ-123 levels after administration of SZ-123. (B) VWF occupancy after administration of SZ-123. (C) Ex vivo inhibition by SZ-123 on Rhesus monkey VWF binding to collagen. (D) Correlation between ex vivo VWF occupancy and inhibition of VWF binding to collagen.

Zhao, Y. M., Jiang, M., Ji, S. D., He, Y., Shen, F., Li, X. M., & Ruan, C. G. (2013). Anti-human VWF monoclonal antibody SZ-123 prevents arterial thrombus formation by inhibiting VWF-collagen and VWF-platelet interactions in Rhesus monkeys. Biochemical Pharmacology, 85(7), 945-953.

Figure 4 SZ-123 inhibits VWF-dependent platelet agglutination.

Ex vivo inhibition of SZ-123 on ristocetin-induced Rhesus monkey platelet agglutination. Platelet agglutination was measured immediately after addition of 2.5 mg/mL ristocetin to PRP samples at each time point as indicated.

Zhao, Y. M., Jiang, M., Ji, S. D., He, Y., Shen, F., Li, X. M., & Ruan, C. G. (2013). Anti-human VWF monoclonal antibody SZ-123 prevents arterial thrombus formation by inhibiting VWF-collagen and VWF-platelet interactions in Rhesus monkeys. Biochemical Pharmacology, 85(7), 945-953.

Figure 5 SZ-123 does not affect VWF levels, platelet count, bleeding time, or coagulation

(A) No significant changes in platelet count were observed in animals after being treated with SZ-123 when compared with the t=0 injection of SZ-123. (B) Plasma VWF antigen levels were not affected by any treatment and no significant changes observed in after treated versus before SZ-123 injection.

Zhao, Y. M., Jiang, M., Ji, S. D., He, Y., Shen, F., Li, X. M., & Ruan, C. G. (2013). Anti-human VWF monoclonal antibody SZ-123 prevents arterial thrombus formation by inhibiting VWF-collagen and VWF-platelet interactions in Rhesus monkeys. Biochemical Pharmacology, 85(7), 945-953.

Figure 6 SZ-123 enhances VWF A3 binding to VWF A1 and inhibits the interaction between VWF A1 and GPIba.

(A) Radioimmunoassays measuring ¹²⁵I-rVWF A3 binding to rVWF A1 coated on microtiter plates. (B) ¹²⁵I-rVWF A3 binding to microtiter plates coated with rVWF A1 Binding assays were performed in the presence of different anti-VWF mAbs. (C) ¹²⁵I-rVWF A1 was able to bind dose-dependently to rGPIba (H1-V289) induced by ristocetin. (D) SZ-123 but not 82D6A3 or SZ-34 inhibited ¹²⁵I-rVWF A1 binding to rGPIba.

Zhao, Y. M., Jiang, M., Ji, S. D., He, Y., Shen, F., Li, X. M., & Ruan, C. G. (2013). Anti-human VWF monoclonal antibody SZ-123 prevents arterial thrombus formation by inhibiting VWF-collagen and VWF-platelet interactions in Rhesus monkeys. Biochemical Pharmacology, 85(7), 945-953.